Here’s what you should know:
1. Researchers discovered CK1alpha agonists. CRC cells have low levels of CK1alpha. In preclinical studies, the agonists have shown “profound efficacy without the associated toxicity.”
2. Other treatments that block the WNT pathway often exhibited “significant” gastrointestinal toxicity issues.
3. StemSynergy’s Director of Medicinal Chemistry Darren Orton, MD, said in a release, “We are extremely pleased with the results of this study.”
4. StemSyngery said the company plans to start phase I clinical trials within a year.
More articles on gastroenterology:
Gastro Health acquires Digestive Health Physicians — 4 key notes
New York hospital planning surgery center — 4 key notes
Proton pump inhibitors associated with excessive death risk, study says — AGA responds
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
